Robert Ross, MD
Robert Ross, MD
Rob joined Clasp Therapeutics in November 2023. He most recently served as the Chief Executive Officer and a member of the Board of Directors of Surface Oncology, Inc. before its acquisition by Coherus Biosciences. Before Surface, Rob served as the Head of Oncology at bluebird bio, Inc. Earlier in his career, Rob worked at Genentech and Infinity Pharmaceuticals, Inc. Rob was a Fellow in Medical Oncology and a faculty member at the Dana Farber Cancer Institute (DFCI). He received a B.S. in Biological Sciences and a B.A. in Philosophy from Stanford University, an M.S. in Medical Science from Harvard Medical School and an M.D. from Columbia University College of Physicians and Surgeons. He completed his residency training in Internal Medicine at the University of California, San Francisco. Rob is an independent Director on the boards of Obsidian Therapeutics, Inc. and Xilio Therapeutics.